XNASCOYA
Market cap89mUSD
Jan 17, Last price
5.38USD
1D
-3.93%
1Q
-32.75%
IPO
13.55%
Name
Coya Therapeutics Inc
Chart & Performance
P/E
—
P/S
14.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
6m
Net income
-8m
L-45.58%
CFO
-11m
L+54.56%
Profile
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 6,002 | |||
Cost of revenue | 13,362 | 9,812 | ||
Unusual Expense (Income) | ||||
NOPBT | (7,360) | (9,812) | ||
NOPBT Margin | ||||
Operating Taxes | 724 | 2,433 | ||
Tax Rate | ||||
NOPAT | (8,084) | (12,245) | ||
Net income | (7,988) -45.58% | (14,678) 201.37% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 38,335 | 158 | ||
BB yield | -50.90% | 0.00% | ||
| Debt | ||||
Debt current | ||||
Long-term debt | 12,965 | |||
Deferred revenue | 575 | |||
Other long-term liabilities | ||||
Net debt | (32,627) | 7,032 | ||
| Cash flow | ||||
Cash from operating activities | (11,189) | (7,239) | ||
CAPEX | ||||
Cash from investing activities | (543) | (525) | ||
Cash from financing activities | 38,425 | 9,358 | ||
FCF | (12,298) | (12,217) | ||
| Balance | ||||
Cash | 32,627 | 5,934 | ||
Long term investments | ||||
Excess cash | 32,327 | 5,934 | ||
Stockholders' equity | (25,855) | (9,075) | ||
Invested Capital | 62,065 | 13,647 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 10,164 | 9,948 | ||
Price | 7.41 56.39% | 4.74 | ||
Market cap | 75,314 59.79% | 47,134 | ||
EV | 42,687 | 62,960 | ||
EBITDA | (7,333) | (9,785) | ||
EV/EBITDA | ||||
Interest | 2,433 | |||
Interest/NOPBT | ||||